BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
Initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20
Named Donnie McGrath as BioShin President and Executive Chairman, and Karl Lintel as BioShin Chief... Biopharmaceuticals, Personnel, Venture Capital Biohaven Pharmaceutical Holding Company, BioShin , NURTEC ODT
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Ataxia | Brain | China Health | Funding | Headache | Migraine | Neurology | Pharmaceuticals | Study | Venture Capital